Pharma CEOs warn EU of potential US exodus as trade war continues
Executives of major pharmaceutical companies warned the European Union that they’re likely to take the US’ side amid the threat of new tariffs. The European Federation of Pharmaceutical Industries and...
View ArticlePharma is next in line as Trump says tariffs are coming 'very shortly'
President Donald Trump warned on Tuesday evening that “major” pharmaceutical tariffs will be coming “very shortly,” after previously exempting drugs from his earlier levy announcements. “We’re gonna do...
View ArticleNovo Nordisk looks to Brazil to boost GLP-1 manufacturing with $1B+ budget
Novo Nordisk is pouring 6.4 billion Brazilian reais ($1.05 billion) into a factory in Brazil, to ramp up production of its blockbuster GLP-1 drugs after it forecast relatively sluggish growth earlier...
View ArticleIdorsia’s blood pressure pill no longer requires a REMS; Solu raises $41M
Plus, news about Vincerx and Cytora: Idorsia’s Tryvio gets safety restriction removed: Patients taking Idorsia’s blood pressure pill no longer have to take part in a drug safety program. The FDA ...
View ArticleBiotech market meltdown will leave some startups looking at survival playbook
It’s a biotech environment without many good choices. Even before President Donald Trump’s tariff announcement pushed stock indices toward a bear market, biotech M&A has been virtually nonexistent,...
View ArticleICER outlines ways to increase GLP-1 access as costs rise
The nonprofit drug pricing watchdog, the Institute for Clinical and Economic Review, on Wednesday released a new report outlining potential federal policy solutions to increase access to blockbuster...
View ArticleFirings of HHS' probationary workers can proceed, appeals court says
HHS and 19 other government agencies can follow through with firing thousands of probationary workers after a federal appeals court paused a lower court's order. Wednesday's ruling by the US Court of ...
View ArticleExclusive: Cardiometabolic biotech gets $57.5M Series B, with help from...
A biotech incubated by RA Capital has secured a $57.5 million Series B to begin a mid-stage trial for its cardio drug this quarter and get to a readout in late 2026. Imbria Pharmaceuticals has ...
View ArticleStudy: Therapy AI chatbot shows promising results
A trial of an AI chatbot built for mental health treatment has shown that it can reduce symptoms of conditions like anxiety and depression. The study published in NEJM AI ran ...
View ArticleBiotech CEOs to Cassidy: We're already seeing the effects of FDA's staff cuts
Biopharma companies with pending applications at the FDA have "already encountered regulatory difficulties that we believe are the consequences of the FDA’s loss of experienced staff," more than 100...
View ArticleAlzheon’s amyloid-targeting pill fails another Alzheimer’s Phase 3
Alzheon’s controversial, decade-long bet that a failed Alzheimer’s drug could offer bigger benefits to a subset of patients at the highest risk for the disease has ended in another disappointment. On...
View Article#AAN25: J&J, argenx keep rolling out myasthenia gravis data, plus more
Last weekend, researchers gathered in San Diego for the American Academy of Neurology’s annual meeting to discuss the latest advancements and clinical trial data across the neuroscience field. Among...
View ArticleDHL pours €2B into healthcare logistics; OXB revenues on the rise
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. DHL Group is spending €2 billion ($2.2 billion) over the next five...
View ArticleInsight Partners' Scott Barclay on mental health investing
For years, investors have poured billions into mental health startups, making it the top-funded area in digital health. But it’s possible we still haven’t seen the company that’s going to ...
View ArticleRFK Jr. talks vaccines, job cuts in his first network interview as HHS chief
In the roughly two months since Robert F. Kennedy Jr. took over as head of HHS, his public appearances have been largely curated and controlled, with limited questions from reporters about his tenure...
View ArticleNovartis follows Lilly and J&J in announcing multibillion-dollar US...
With US tariffs on pharmaceuticals likely to come "very soon," another of the world's largest drugmakers is announcing plans to beef up their American manufacturing. On Thursday, Swiss-based Novartis...
View ArticleFDA is reversing return-to-office mandate for some workers
Less than a month after the Trump administration ordered all FDA employees to come back to their offices full-time, agency leaders have told some staff that remote work will return, multiple FDA ...
View ArticleIra Mellman joins PICI; ViiV Healthcare CMO replaces Chris Corsico at GSK
After 17 years at Genentech, Ira Mellman is joining the Parker Institute for Cancer Immunotherapy as president of research. The PICI, founded by tech entrepreneur Sean Parker, is a key funder ...
View ArticleTome Bio founders wrangle ‘jumping genes’ for new gene insertion tool
Two Boston scientists say they have developed a new gene editing tool based on mysterious "jumping genes" known as retrotransposons, which can copy and paste themselves to hop around the genome. While...
View ArticleCDMOs anticipate inspection bottlenecks after FDA firings
CDMOs fear that FDA site inspections might slow down due to the mass staffing cuts at the federal health agencies. While President Donald Trump's potential pharma tariffs have all drugmakers on alert ...
View ArticleArgenx’s Vyvgart Hytrulo syringe is approved in the US; Opthea to cut 65% of...
Plus, news about Protagonist Therapeutics, Pfizer and Keros Therapeutics: Argenx wins FDA approval for Vyvgart Hytrulo syringe: The subcutaneous injection, which comes in a more convenient prefilled...
View ArticleRecruiters say some biopharmas pause hiring as they struggle to make sense of...
An already bleak biotech market has become more daunting for job seekers, particularly executives. It’s a gut punch for those who have been holding out hope for brighter days since 2022, when the...
View Article